NinaDelaneyWagner-JohnstonMD

Oncology • Baltimore, MD

Assistant Professor, Internal Medicine, Washington University School of Medicine

Join to view full profile

Dr. Wagner-Johnston is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Wagner-Johnston's full profile

Already have an account?

Office
401 North Broadway Street
Weinberg BLDG
Baltimore, MD 21287
Phone+1 410-955-8964

Fax+1 410-367-2194

Education & Training

Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 2005 - 2008
University of ChicagoResidency, Internal Medicine, 2003 - 2005
University of Chicago Division of the Biological Sciences The Pritzker School of MedicineClass of 2003

Certifications & Licensure

DC State Medical License 2022 - 2026
MD State Medical License 2005 - 2025
PA State Medical License 2024 - 2024
MO State Medical License 2008 - 2016
IL State Medical License 2003 - 2006
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification Allscripts Enterprise EHR, Allscripts, 2012

Clinical Trials

Study of Blood and Tissue Samples From Patients With Aggressive Non-Hodgkin B-Cell Lymphoma or Hodgkin Lymphoma Start of enrollment: 2009 Aug 01
Completed
Evaluate the Efficacy of Armodafinil for Patients With B-cell Lymphoma and Severe Fatigue Start of enrollment: 2010 Mar 01
Withdrawn
Not Applicable
Combination Chemotherapy With or Without Autologous Stem Cell Transplant in Treating Patients With Central Nervous System B-Cell Lymphoma Start of enrollment: 2012 Sep 01
Active, not recruiting
Phase 2
Phase I/II Study of Abraxane in Recurrent and Refractory Lymphoma Start of enrollment: 2012 Jul 01
Terminated
Phase 1
Study of Rituximab and Brentuximab Vedotin for Relapsed Classical Hodgkin Lymphoma Start of enrollment: 2014 Jun 01
Terminated
Phase 1
Efficacy and Safety of Idelalisib in Combination With Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia With 17p Deletion Start of enrollment: 2014 Aug 06
Terminated
Phase 2
Brentuximab Vedotin and Lenalidomide for Relapsed or Refractory Diffuse Large B-cell Lymphoma Start of enrollment: 2014 Sep 18
Completed
Phase 1
Falls Risk Questionnaire in Older Adults With Cancer Start of enrollment: 2014 Aug 01
Completed
Perspectives on Bone Marrow Donors Who Donate for Their Parent Start of enrollment: 2016 Dec 06
Completed
Non-Invasive Neurosensory Testing For Chemotherapy-Induced Peripheral Neuropathy Start of enrollment: 2017 Nov 29
Completed
A Comparison of Three Chemotherapy Regimens for the Treatment of Patients With Newly Diagnosed Mantle Cell Lymphoma Start of enrollment: 2019 Dec 13
ACTIVE_NOT_RECRUITING
PHASE2
HMPL-760 Safety and Tolerability Study in Patients With Previously Treated CLL/SLL or NHL Start of enrollment: 2022 Feb 15
Withdrawn
Phase 1
Roles: Contact, Principal Investigator
Join now to see all

Publications & Presentations

PubMed

Improved overall survival with checkpoint inhibition and allogeneic transplantation in relapsed Hodgkin lymphoma.
Nadeem Tabbara, Marianna Zahurak, Cole H Sterling, Iris Margalit Trutzer, Jaroslaw Jedrych
Blood Advances. 2025-03-11
3 citations
Myeloablative vs nonmyeloablative consolidation for primary central nervous system lymphoma: results of Alliance 51101.
Tracy T Batchelor, Sharmila Giri, Amy S Ruppert, Susan M Geyer, Scott E Smith
Blood Advances. 2024-06-25
12 citations
TRBC1-targeting antibody-drug conjugates for the treatment of T cell cancers.
Tushar D Nichakawade, Jiaxin Ge, Brian J Mog, Bum Seok Lee, Alexander H Pearlman
Nature. 2024-04-01

Abstracts/Posters

A Phase IB Study of Blinatumomab (blina) in Patients with B Cell Acute Lymphoblastic Leukemia (ALL) and B-Cell Non-Hodgkin Lymphoma (NHL) As Post-Allogeneic Blood or M...
Nina D. Wagner-Johnston, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Correlative Analyses of Patient and Clinical Characteristics Associated with Efficacy in Tisagenlecleucel-Treated Relapsed/Refractory Diffuse Large B-Cell Lymphoma Pat...
Nina D. Wagner-Johnston, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Allogenic Stem Cell Transplantation for Secondary CNS Lymphoma: A Retrospective Review of 21 Patients
Nina D. Wagner-Johnston, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Impact of Tisagenlecleucel Chimeric Antigen Receptor (CAR)-T Cell Therapy Product Attributes on Clinical Outcomes in Adults with Relapsed or Refractory Diffuse Large B...
Nina D. Wagner-Johnston, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Correlation of Bridging and Lymphodepleting Chemotherapy with Clinical Outcomes in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Treated with Tisagen...
Nina D. Wagner-Johnston, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Join now to see all

Lectures

Long-Term Follow-up of Idelalisib Monotherapy in Patients with Double-Refractory Marginal Zone Lymphoma or Lymphoplasmacytic Lymphoma/ Waldenstrom's Macroglobulinemia
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Checkpoint Blockade Therapy May Sensitize Aggressive and Indolent Non-Hodgkin Lymphoma to Subsequent Therapy
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Checkpoint Blockade Therapy May Sensitize Hodgkin Lymphoma to Subsequent Therapy
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Sustained Disease Control for Adult Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: An Updated Analysis of Juliet, a Global Pivotal Phase 2 Trial o...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Making Strides in the Treatment of B-Cell Malignancies: Keeping Up With New Data and Practice Recommendations
60th American Society of Hematology Annual Meeting - 11/30/2018
Join now to see all

Press Mentions

Treatment Options in MCL: What Are the Best Practices?September 12th, 2024
Pain PointersJune 1st, 2021
Dual Expression of MYC, BCL2 Associated with Poorer Outcomes in DLBCLMay 26th, 2017

Grant Support

Addressing Underperformance in Clinical Trial Enrollments: Development of a Clinical Trial Toolkit and Expansion of the Clinical Research FootprintJOHNS HOPKINS UNIVERSITY2023–2028
Addressing Underperformance in Clinical Trial Enrollments: Development of a Clinical Trial Toolkit and Expansion of the Clinical Research FootprintJOHNS HOPKINS UNIVERSITY2023–2028